More funding for leishmaniasis treatment could save more lives in East African outbreak

NewsGuard 100/100 Score

"East Africa's worst outbreak in a decade of visceral leishmaniasis, the deadliest parasitic disease after malaria, could ease if donors paid more attention to the illness," which infects approximately 500,000 people and kills up to 60,000 annually in 70 countries, the non-profit group "Leishmaniasis East Africa Platform, or LEAP, said in a statement from Nairobi" on Friday, Bloomberg reports.

Additional funding to fight the disease would allow for increased access to a new shorter and more affordable combination treatment developed by LEAP and the Drugs for Neglected Diseases initiative and approved by the WHO, according to the news agency. The disease, also called kala azar, is spread through the bite of infected sand flies and usually kills within two years if untreated, the news agency notes (McGregor, 9/23).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show